Addex Therapeutics Announces Positive Preclinical Data for GABAB PAM in Chronic Cough IPF Model

On April 29, 2026, Addex Therapeutics announced positive preclinical data for its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. The study demonstrated robust and sustained antitussive efficacy, showing significant reductions in cough frequency and increased cough latency with chronic once-daily administration. Beyond cough suppression, the candidate showed improved lung pathology outcomes, including lower Ashcroft scores and reduced affected lung tissue, suggesting a potential impact on fibrosis. The safety profile remained favorable, with no meaningful changes in respiratory rate or body temperature, and the compound was well tolerated throughout the study. This data builds on recent non-human primate studies and supports the development of GABAB PAM as a novel, well-tolerated approach for chronic cough management, aiming to avoid the sedative side effects and efficacy loss associated with orthosteric agonists like baclofen. Addex continues to advance this independent GABAB PAM program alongside its partnered programs with Indivior and its interest in Neurosterix LLC.